1. Home
  2. BOH vs EWTX Comparison

BOH vs EWTX Comparison

Compare BOH & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bank of Hawaii Corporation

BOH

Bank of Hawaii Corporation

N/A

Current Price

$73.77

Market Cap

2.8B

Sector

Finance

ML Signal

N/A

Logo Edgewise Therapeutics Inc.

EWTX

Edgewise Therapeutics Inc.

N/A

Current Price

$30.97

Market Cap

3.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BOH
EWTX
Founded
1897
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.8B
3.3B
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
BOH
EWTX
Price
$73.77
$30.97
Analyst Decision
Hold
Buy
Analyst Count
5
8
Target Price
$80.40
$36.00
AVG Volume (30 Days)
422.7K
704.0K
Earning Date
01-01-0001
05-27-2026
Dividend Yield
3.78%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$15.66
N/A
Revenue Next Year
$7.82
N/A
P/E Ratio
$17.08
N/A
Revenue Growth
N/A
N/A
52 Week Low
$57.45
$10.60
52 Week High
$80.61
$31.82

Technical Indicators

Market Signals
Indicator
BOH
EWTX
Relative Strength Index (RSI) 41.55 59.52
Support Level $65.63 $28.56
Resistance Level $79.43 $31.12
Average True Range (ATR) 2.49 1.42
MACD -0.73 -0.12
Stochastic Oscillator 18.04 82.79

Price Performance

Historical Comparison
BOH
EWTX

About BOH Bank of Hawaii Corporation

Bank of Hawaii Corp provides a broad range of financial products and services predominantly to customers in Hawaii, Guam, and other Pacific Islands. The Bank's subsidiaries are engaged in equipment leasing, securities brokerage, investment advisory services, and providing credit insurance. It is organized into three business segments for management reporting purposes: Consumer Banking, Commercial Banking, and Treasury and Other. Majority of the revenue is generated from Consumer Banking segment which offers a broad range of financial products and services, including loan, deposit and insurance products; private banking and international client banking services; trust services; investment management; and institutional investment advisory services.

About EWTX Edgewise Therapeutics Inc.

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.

Share on Social Networks: